Core Viewpoint - Zhaoyan New Drug has shown significant stock price growth in 2023, with a year-to-date increase of 111.57% and a recent market capitalization of 26.322 billion yuan [1] Group 1: Stock Performance - As of September 12, Zhaoyan New Drug's stock price reached 35.12 yuan per share, with a trading volume of 7.81 billion yuan and a turnover rate of 3.58% [1] - The stock has experienced a 3.26% increase over the last five trading days, a 6.55% increase over the last 20 days, and an 87.91% increase over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on July 29 [1] Group 2: Financial Performance - For the first half of 2025, Zhaoyan New Drug reported a revenue of 669 million yuan, a year-on-year decrease of 21.28%, while the net profit attributable to shareholders increased by 135.90% to 60.9324 million yuan [2] - Since its A-share listing, the company has distributed a total of 703 million yuan in dividends, with 356 million yuan distributed over the past three years [3] Group 3: Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 25.59% to 61,200 [2] - The top five circulating shareholders include Huabao Zhongzheng Medical ETF, which increased its holdings by 2.2669 million shares, and Hong Kong Central Clearing Limited, which reduced its holdings by 943,870 shares [3]

9月10日早盘，医疗板块低开后快速回暖，CXO概念强劲反弹，昭衍新药涨停，康龙化成涨超5%，巨 头药明康德涨超2%。 消息面上，Grand View Research预测，全球CXO市场规模有望从2024年的1970亿美元增长至2030年的 2980亿美元，期间年复合增速为7%，略高于同期全球制药市场6%的年复合增速。 从估值来看，医疗ETF（512170）标的指数中证医疗最新PE估值约为36倍，仍低于近10年逾60%时间区 间，配置性价比相对突出。 牛市"高切低"，关注医疗估值洼地。配置工具认准A股最大医疗ETF（512170）及其联接基金 （012323）：聚焦"医疗器械（52%）+医疗服务（40%）"，与AI医疗高相关，覆盖6只CXO龙头股。截 至9月8日，医疗ETF（512170）规模275亿元，同类规模最大；年初以来日均成交6.45亿元，流动性优 秀。 风险提示：医疗 ETF 及其联接基金被动跟踪中证医疗指数，该指数基日为 2004.12.31 ，发布于 2014.10.31 。 中 证 医 疗 指 数 2020 年 至 2024 年 的 分 年 度 业 绩 分 别 为 79.67% 、 -14.7 ...

Core Viewpoint - The innovative drug concept stocks are experiencing significant activity, with notable gains in several companies, indicating a positive trend in the pharmaceutical sector [1] Company Summaries - Zhaoyan New Drug has reached its daily limit increase, reflecting strong investor interest and confidence in its growth potential [1] - MediXis, Kanglong Chemical, Haixiang Pharmaceutical, Kailaiying, and Jiuzhou Pharmaceutical have also seen upward movement in their stock prices, suggesting a broader rally in the innovative drug sector [1]

证券之星消息，9月9日医疗服务板块较上一交易日下跌2.94%，昭衍新药领跌。当日上证指数报收于 3807.29，下跌0.51%。深证成指报收于12510.6，下跌1.23%。医疗服务板块个股涨跌见下表： 从资金流向上来看，当日医疗服务板块主力资金净流出17.25亿元，游资资金净流入4.63亿元，散户资金 净流入12.62亿元。医疗服务板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 603127 | 昭衍新药 | 32.22 | -7.01% | 47.36万 | 15.66亿 | | 688222 | 成都先导 | 25.13 | -6.79% | 25.48万 | 6.60亿 | | 835670 | 数字人 | 17.97 | -6.60% | 9.56万 | 1.76亿 | | 002173 | 创新医疗 | 22.49 | -5.74% | ...

Core Viewpoint - Zhaoyan New Drug (603127) experienced a decline of over 7%, with a current price of 20.98 HKD and a trading volume of 147 million HKD [1] Group 1: Shareholder Reduction Plans - On September 8, Zhaoyan New Drug announced that several executives, including Vice General Manager Sun Yunxia and General Manager Gao Dapeng, plan to reduce their holdings between September 30, 2025, and November 28, 2025, through Shanghai Stock Exchange transactions, with a total reduction not exceeding 84,830 shares, representing 0.1132% of the company's total share capital [1] - Previously, on September 1, the company disclosed that former Vice Chairman Zuo Conglin planned to reduce his holdings from August 19, 2025, to August 29, 2025, with a maximum reduction of 3,524,500 shares, which was 0.4703% of the company's total share capital at that time [2] - As of August 29, 2025, Zuo Conglin had reduced his holdings by 2,264,900 shares through concentrated bidding, completing his reduction plan [2]

Core Viewpoint - Zhaoyan New Drug (06127) experienced a decline of over 7%, closing at HKD 20.98 with a trading volume of HKD 147 million due to insider selling announcements [1] Group 1: Insider Selling Announcements - On September 8, Zhaoyan New Drug announced that several executives, including Vice General Manager Sun Yunxia and General Manager Gao Dapeng, plan to reduce their holdings between September 30, 2025, and November 28, 2025, through block trades or centralized bidding on the Shanghai Stock Exchange, with a total reduction not exceeding 84,830 shares, representing 0.1132% of the company's total share capital [1] - The planned reductions include 674,700 shares from Sun Yunxia, 72,100 shares from Gao Dapeng, and 67,400 shares from Gu Jingliang, along with additional reductions from supervisor Li Ye and CFO Yu Aishui [1] Group 2: Previous Insider Selling - On September 1, Zhaoyan New Drug disclosed that former Vice Chairman Zuo Conglin had a reduction plan announced on August 14, 2025, intending to sell up to 3,524,500 shares between August 19, 2025, and August 29, 2025, which would account for 0.4703% of the company's total share capital at that time [2] - By August 29, 2025, Zuo Conglin had successfully reduced his holdings by 2,264,900 shares through centralized bidding [2]

Group 1 - Hanbang Technology received a decision from the National Intellectual Property Administration declaring the patent rights of Cytiva's "separation medium slurry tank" invalid, reflecting the principle of equal treatment in China's intellectual property protection system [1] - Zhaoyan New Drug announced that its directors and executives plan to reduce their holdings in the company due to personal financial needs, which may raise short-term stock price concerns among investors [2] - Zhixiang Jintai obtained approval for clinical trials of its GR2303 injection, a monoclonal antibody targeting TL1A for treating inflammatory bowel disease, indicating significant clinical development value [3] Group 2 - Lude Medical's actual controller plans to reduce his holdings by 2.48 million shares, accounting for 1.4212% of the total share capital, reflecting urgent personal financial needs [4] - Buchang Pharmaceutical's subsidiary is set to invest in a new company, Shaanxi Buchang Medical Data Pharmaceutical Co., Ltd., aiming to integrate pharmaceutical resources with digital capabilities, aligning with the trend of digital transformation in the pharmaceutical industry [5]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603127 证券简称：昭衍新药 公告编号：2025-039 北京昭衍新药研究中心股份有限公司 董事、监事及高管减持A股股份计划公告 一、减持主体的基本情况 ■ 注：其他方式是指股权激励及公司资本公积金转增股份等。 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 董监高持股的基本情况 截至本公告披露日，北京昭衍新药研究中心股份有限公司（以下简称"公司"）董事、副总经理孙云霞持 有公司股票2,698,907股，占公司总股本0.3601%；董事、总经理、董事会秘书高大鹏持有公司股票 288,746股，占公司总股本0.0385%；董事、副总经理顾静良持有公司股票269,801股，占公司总股本 0.0360%；监事李叶持有公司股票102,481股，占公司总股本0.0137%；财务总监于爱水持有公司股票 34,104股，占公司总股本0.0046%。上述股份来源于首发前限售股份、股权激励股份及公司资本公积金 转增股份等。 ● 减持计划的主要内容 孙云 ...

Summary of Key Points - The company Zhaoyan New Drug announced a share reduction plan involving several key individuals [2] - The planned reduction will occur from September 30, 2025, to November 28, 2025, through block trading or centralized bidding on the Shanghai Stock Exchange [2] - The total shares to be reduced amount to 848,300, which represents approximately 0.1132% of the company's current total share capital [2]

北京昭衍新药研究中心股份有限公司 董事、监事及高管减持 A 股股份计划公告 证券代码：603127 证券简称：昭衍新药 公告编号：2025-039 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 董监高持股的基本情况 孙云霞、高大鹏、顾静良拟自本减持计划公告之日起 15 个交易日后即 2025 年 9 月 30 日至 2025 年 11 月 28 日，通过上海证券交易所大宗交易或集中竞价的 方式分别减持不超过 674,700 股、72,100 股、67,400 股；李叶、于爱水拟自本减 持计划公告之日起 15 个交易日后即 2025 年 9 月 30 日至 2025 年 11 月 28 日，通 过上海证券交易所集中竞价的方式分别减持不超过 25,600 股、8,500 股,前述减持 合计不超过 848,300 股，不超过公司当前总股本的 0.1132%。减持计划实施期间， 公司若发生送红股、转增股本、增发新股或配股等股本除权事项的，减持数量将 进行相应调整。减持价格依据市场价格确定。 | 股东名称 | ...